CR Double-Crane Unveils Q1 2025 Financial Results

Get Ahead of the Market:

  • Find top-performing stocks and invest more intelligently with Top Smart Score Stocks.
  • Use filters, conduct analysis, and optimize your search for investment opportunities utilizing this method. Cryptonesia' Stock Screener.

China Resources Pharmaceutical Group Co., Ltd. ( (HK:3320) ) has issued an announcement.

CR Double-Crane has issued its unverified financial outcomes for Q1 of 2025, showing a minor dip in revenues from the prior year yet highlighting an uptick in net earnings. Although the firm’s overall assets and shareholders' equity have expanded, cash and cash reserves have declined. Investors should remain cautious since these figures haven’t been audited and could undergo revisions.

Further Details on China Resources Pharmaceutical Group Ltd.

China Resources Double-Crane Pharmaceutical Co., Ltd. is a pharmaceutical firm established in China, whose stocks are traded on the Shanghai Stock Exchange. This company operates as a subsidiary under China Resources Pharmaceutical Group Limited, which possesses an indirect stake of 60.24%.

YTD Price Performance: -19.26%

Average Trading Volume: 1,550

Technical Sentiment Signal: Buy

Current Market Cap: €3.5B

Explore further insights into 3320 stock on Cryptonesia’ Stock Analysis page .

Disclaimer & Disclosure Report an Issue

Related Posts

0 Response to "CR Double-Crane Unveils Q1 2025 Financial Results"

Post a Comment

Iklan Atas Artikel

Iklan Tengah Artikel 1

Iklan Tengah Artikel 2

Iklan Bawah Artikel